|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000038388 |
|
最近更新日期: Date of Last Refreshed on: |
2020-12-20 20:16:23 |
|
注册时间: Date of Registration: |
2020-09-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新生儿脓毒症及其严重并发症的预警与早期诊断的多中心临床研究 |
|
Public title: |
Multi center clinical study on early warning and early diagnosis of neonatal sepsis and its serious complications |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新生儿脓毒症及其严重并发症的预警与早期诊断的多中心临床研究 |
|
Scientific title: |
Multi center clinical study on early warning and early diagnosis of neonatal sepsis and its serious complications |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张璐 |
研究负责人: |
周晓光 |
|
Applicant: |
Zhang Lu |
Study leader: |
Zhou Xiaoguang |
|
申请注册联系人电话: Applicant telephone: |
+86 18351977923 |
研究负责人电话: Study leader's telephone: |
+86 18951769771 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangluabc@126.com |
研究负责人电子邮件: Study leader's E-mail: |
gzzhouxg@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市鼓楼区广州路72号 |
研究负责人通讯地址: |
江苏省南京市鼓楼区广州路72号 |
|
Applicant address: |
72 Guangzhou Road, Gulou District, Nanjing, Jiangsu, China |
Study leader's address: |
72 Guangzhou Road, Gulou District, Nanjing, Jiangsu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京医科大学附属儿童医院 |
||
|
Applicant's institution: |
Children's Hospital Affiliated to Nanjing Medical University |
||
|
研究负责人所在单位: |
南京医科大学附属儿童医院 |
||
|
Affiliation of the Leader: |
Children's Hospital Affiliated to Nanjing Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
202004015-1 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京医科大学附属儿童医院医学伦理委员会 |
||
|
Name of the ethic committee: |
IEC of Children's Hospital of Nanjing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-04-24 00:00:00 |
||
|
伦理委员会联系人: |
黄松明 |
||
|
Contact Name of the ethic committee: |
Huang Songming |
||
|
伦理委员会联系地址: |
南京市建邺区江东南路8号南京医科大学附属儿童医院河西院区 |
||
|
Contact Address of the ethic committee: |
Hexi District, Children's Hospital Affiliated to Nanjing Medical University, 8 Dongnan Road, Jianye District, Nanjing, Jiangsu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
南京医科大学附属儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Children's Hospital Affiliated to Nanjing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市鼓楼区广州路72号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
72 Guangzhou Road, Gulou District, Nanjing, Jiangsu, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financing |
||||||||||||||||||||||
|
Target disease: |
Neonatal Sepsis and Intracranial Infection(acute meningitis and encephalitis syndrome)/ sepsis shock |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
1、了解我国新生儿脓毒症及其严重并发症(脓毒性休克、AMES等)的临床特征,为制订新生儿脓毒症诊断标准及防治措施提供可靠资料。 2、获得我国新生儿脓毒症的病原谱,评估mNGS对疑似或证实的新生儿脓毒症及其严重并发症(脓毒性休克、AMES等)的病原学诊断效能,评估 IL-6、钙卫蛋白、Pro-ADM、HBP、PTX-3等新型感染相关生物学标志物对新生儿脓毒症的早期诊断价值,寻找更为灵敏、特异的生物学标志物,为更全面地研究新生儿感染性疾病奠定基础。 3、开展病原宏基因组学/宏转录组学检测,进行病原体鉴定分型/相对定量、耐药基因预测、毒力因子分析、宿主转录组学与免疫反应分析,从病原体、宿主和药物三个维度指导临床实施新生儿感染性疾病的精准医疗,进而达到降低我国新生儿脓毒症的发病率、死亡率及后遗症发生率的效果。 4、建立新生儿脓毒症及其严重并发症(脓毒性休克、AMES等)患儿体格发育与神经发育的研究队列,进行长期随访,以评估患儿近远期预后。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.We hope to understand the clinical epidemiological characteristics of neonatal sepsis and its severe complications (AMES and shock) in China, thus we could provide first-hand information for formulating a strategy of neonatal sepsis and AMES prevention and treatment. 2.We expect to obtain the pathogenic spectrum of neonatal sepsisin China, to evaluate the etiological diagnosis efficacy of mNGS and biomarkers such as IL-6 for neonatal sepsis and to establish a database of neonatal infectious pathogenic microorganisms ,so we could be able to lay the foundation for more comprehensive research on neonatal infectious diseases. 3.We plan to carry out pathogen metagenomics / metatranomics detection and conduct pathogen identification and typing / relative quantification, drug resistance gene prediction, virulence factor analysis, host transcriptomics and immune response analysis. Through this three dimensions--pathogens, hosts and drugs, we could get guidance for our clinical implementation of precision medicine for neonatal infectious diseases, which could help reduce the morbidity, mortality and sequelae of neonatal sepsis in China. 4.We aim to conduct a cohort study of chilerens physical and neural development with neonatal sepsis and its severe complications, and follow them up long-term to evaluate the short-term and long-term prognosis of these children. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
研究期间各协作医院收治的胎龄28~42周、日龄0~28天的新生儿,入院时疑诊为新生儿脓毒症,合并/不合并脓毒性休克或AMES。 |
||||||||||||||||||||||
|
Inclusion criteria |
During the study period, newborns with gestational age of 28-42 weeks and gestational age of 0-28 days were suspected of neonatal sepsis at admission, with / without septic shock or Ames. |
||||||||||||||||||||||
|
排除标准: |
应排除颅脑肿瘤、 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with brain tumor; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-01-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2021-01-01 00:00:00 至 To 2021-12-31 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本项目拟在我国东北、华北、华东、华中、华南、西北、西南地区等7个不同地区选取具有NICU 建制的三级甲等综合性医院、儿童医院和妇幼保健院的新生儿科组成研究协作组,选择2021年1月1日至12月31日内各协作医院新生儿科收治的新生儿脓毒症合并、不合并脓毒症休克或AMES患儿为研究对象。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
We are aimed at cooperate with the NICU of 3a general hospitals,children's hospitals and maternal and child health care hospitals from each areas of China ,selecting newborns with sepsis combined with AMES and sepsis shock or not ,from January 1 to December 31,2021,as study subjects . |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
文章发布时共享数据,采用中国临床试验注册中心的临床试验原始数据共享平台 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Sharing data with the artical publication, Chinese Clinical Trial Registry |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用项目组自行设计的网站平台收集并管理数据. |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data will be collected and managed using the website platform designed by the project team. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |